A previous study by Onagi et al (43) demonstrated that in patients with TNBC, a high PLR predominantly includes more CD3+CD4+FOXP3+ T-cells (regulatory T-cells), thus suggesting that local tumor immunity can be suppressed in these patients, eventually leading to poor immunotherapy outcomes. This evidence concerns the gene FOXP3 and neoplasm.